How Many Doses Vial SS-LUP-332? (Reconstitution Guide)

How Many Doses Vial SS-LUP-332? (Reconstitution Guide)

A single 5mg vial of SS-LUP-332 peptide delivers anywhere from 10 to 30 usable doses. But that range isn't arbitrary. The number of doses you extract from one vial depends entirely on your protocol dose and your reconstitution volume, two variables that determine concentration and injection precision. Get the reconstitution wrong and you'll either waste peptide through inaccurate draws or run out of supply mid-cycle without realizing your dilution was off from day one.

Our team works with research labs running SS-LUP-332 protocols across a range of dose escalations. The single most common error we see isn't contamination or storage failure. It's miscalculating how many doses a vial actually contains after reconstitution, leading to either protocol interruption or inconsistent dosing that compromises data integrity.

How many doses can you get from one vial of SS-LUP-332?

A standard 5mg vial of SS-LUP-332 yields 10–30 doses depending on your target dose per injection. If you're running a 250mcg protocol dose, one vial provides 20 doses. If your protocol calls for 500mcg per administration, the same vial gives you 10 doses. Reconstituting with 2mL bacteriostatic water creates a 2.5mg/mL concentration. Each 0.1mL (10 units on a standard insulin syringe) delivers 250mcg of active peptide.

Here's what most peptide guides don't mention: SS-LUP-332's dose-per-vial calculation isn't just about total peptide mass. It's about injectable volume precision. You can't draw 0.02mL accurately with standard research syringes, which means protocols requiring very low doses per administration (under 100mcg) force you into higher reconstitution volumes that dilute concentration but improve measurement accuracy. This article covers the reconstitution math that determines how many doses vial SS-LUP-332 actually provides, the syringe limitations that constrain your dosing options, and the storage timeline that defines your usable window once the vial is mixed.

Reconstitution Volume Determines Dose Count

The number of doses you extract from a vial of SS-LUP-332 is a function of three variables: total peptide mass in the vial (typically 5mg), your target dose per injection, and your reconstitution volume. Most researchers reconstitute 5mg vials with 2mL bacteriostatic water, creating a 2.5mg/mL solution. At this concentration, 0.1mL (10 units on an insulin syringe) delivers 250mcg. Making a 5mg vial good for 20 doses at 250mcg each.

If your protocol calls for 500mcg per dose, the same 2mL reconstitution gives you 10 doses (0.2mL per injection). If you're running a lower-dose protocol at 125mcg, you get 40 theoretical doses. But syringe accuracy becomes the limiting factor. Drawing 0.05mL (5 units) with precision requires a 0.3mL insulin syringe with 1-unit graduations, and even then, measurement error at volumes below 0.1mL introduces variability that can skew dose consistency across a multi-week protocol.

Here's the reconstitution trade-off most guides ignore: higher reconstitution volumes (3mL or 4mL instead of 2mL) lower concentration, which increases injectable volume for the same dose and improves measurement precision. But you're now drawing larger volumes per injection, which means fewer total doses from the same vial if your syringe capacity is limited. A 5mg vial reconstituted with 4mL bacteriostatic water creates a 1.25mg/mL solution. To get 250mcg, you now draw 0.2mL instead of 0.1mL. Cutting your total dose count in half unless you use larger syringes.

Our experience: labs running dose-escalation studies benefit from starting with lower concentrations (3–4mL reconstitution) during the initial low-dose phase, then switching to higher concentrations (1–2mL reconstitution) as protocol doses increase. This keeps injectable volumes within the 0.1–0.3mL sweet spot where standard insulin syringes maintain accuracy.

SS-LUP-332 Protocol Dose Ranges and Vial Lifespan

SS-LUP-332 research protocols typically run doses between 125mcg and 1mg per administration, with frequency ranging from daily to twice-weekly depending on study design. The peptide's mechanism. Selective PPARδ agonism that increases mitochondrial biogenesis and shifts substrate utilization toward fatty acid oxidation. Shows dose-dependent effects in preclinical models, meaning your protocol's dose per injection directly determines how many vials you'll need across a full study timeline.

A 5mg vial reconstituted to 2.5mg/mL concentration supports these dose counts:

125mcg/dose: 40 doses (0.05mL per injection)

250mcg/dose: 20 doses (0.1mL per injection)

500mcg/dose: 10 doses (0.2mL per injection)

1mg/dose: 5 doses (0.4mL per injection)

But here's the constraint nobody talks about: once reconstituted, SS-LUP-332 maintains stability for 28 days when refrigerated at 2–8°C. If your protocol calls for twice-weekly dosing at 250mcg, one vial gives you 20 doses. Which covers 10 weeks of administration, well beyond the 28-day post-reconstitution stability window. You'll discard unused peptide or need to reconstitute a second vial mid-protocol.

The solution: calculate your total doses needed within the 28-day window, then reconstitute only enough peptide to cover that period. If you're dosing 250mcg twice weekly (8 doses per month), reconstitute half a vial (2.5mg) with 1mL bacteriostatic water to create the same 2.5mg/mL concentration. Giving you exactly 10 doses that fit within the stability window. Split-vial reconstitution requires lyophilized peptide to remain dry until the second reconstitution event, so this works only if you have a sterile technique for partial reconstitution or access to smaller vial sizes.

We've guided labs through this exact calculation dozens of times. The waste pattern is consistent: researchers reconstitute full 5mg vials for low-frequency protocols, then discard 50–70% of the peptide when the 28-day mark hits.

Syringe Precision and Measurement Error

The weakest link in determining how many usable doses you get from a vial of SS-LUP-332 isn't the peptide. It's your syringe's measurement precision. Standard 1mL insulin syringes are graduated in 0.01mL increments (1 unit = 0.01mL), which means the smallest volume you can measure with confidence is 0.05mL (5 units). Drawing volumes below that threshold introduces measurement error that compounds across repeat doses.

At 2.5mg/mL concentration, a 0.01mL measurement error represents 25mcg of peptide. A 10% variance if your target dose is 250mcg, and a 20% variance at 125mcg. That level of inconsistency across a 12-week protocol doesn't just reduce statistical power. It makes dose-response analysis nearly impossible because your actual administered doses vary by double-digit percentages from your nominal protocol dose.

Here's what fixes it: match your reconstitution volume to your syringe's precision range. If your protocol requires doses under 250mcg, reconstitute with 3–4mL bacteriostatic water to increase injectable volume and move your draws into the 0.1–0.2mL range where syringe accuracy is highest. If you're running higher doses (500mcg or above), reconstitute with 1–2mL to keep injectable volumes manageable and avoid wasting syringe capacity.

The trade-off: higher reconstitution volumes mean more bacteriostatic water per vial, which increases the total liquid volume you're storing and shortens the effective number of doses per vial. A 5mg vial reconstituted with 4mL at 1.25mg/mL concentration gives you the same 20 doses at 250mcg each. But you're now drawing 0.2mL per dose instead of 0.1mL, so each injection uses twice the volume. If you're limited to 0.3mL syringes, this matters.

Our recommendation: for protocols under 500mcg per dose, reconstitute with 2–3mL. For protocols above 500mcg, reconstitute with 1–2mL. This keeps your draws in the 0.1–0.3mL range where insulin syringes maintain accuracy without forcing you into dilutions so low that you're injecting half a syringe per dose.

SS-LUP-332 Vial Comparison: Dose Yield by Reconstitution Volume

1mL bacteriostatic water

5.0 mg/mL

20 doses

10 doses

0.05mL (5 units)

Low. Syringe error significant

2mL bacteriostatic water

2.5 mg/mL

0.1mL (10 units)

High. Standard insulin syringe optimal

3mL bacteriostatic water

1.67 mg/mL

0.15mL (15 units)

High. Increases volume, maintains precision

4mL bacteriostatic water

1.25 mg/mL

0.2mL (20 units)

Moderate. Larger volume limits max dose per syringe

Key Takeaways

A 5mg vial of SS-LUP-332 yields 10–30 doses depending on protocol dose, with 250mcg/dose protocols delivering 20 doses when reconstituted with 2mL bacteriostatic water.

Reconstitution volume determines concentration. Higher volumes (3–4mL) improve measurement precision for low-dose protocols by increasing injectable volume, while lower volumes (1–2mL) maximize dose count for high-dose protocols.

Once reconstituted, SS-LUP-332 maintains stability for 28 days refrigerated at 2–8°C. Protocols requiring fewer than 8–10 doses per month will waste peptide unless you reconstitute partial vials or adjust dosing frequency.

Syringe precision limits accurate measurement below 0.05mL (5 units on an insulin syringe). Measurement error at low volumes introduces 10–20% dose variance that compromises protocol consistency.

The 2.5mg/mL concentration (5mg vial + 2mL bacteriostatic water) is the optimal balance for most SS-LUP-332 protocols, delivering 250mcg per 0.1mL with high syringe accuracy and 20 total doses per vial.

What If: SS-LUP-332 Dosing Scenarios

What If I Need to Dose Lower Than 125mcg Per Injection?

Reconstitute with 4–5mL bacteriostatic water to create a 1.0–1.25mg/mL solution, which increases injectable volume and allows 0.1mL draws (10 units) to deliver 100–125mcg with standard insulin syringe precision. Your total dose count per vial remains unchanged (a 5mg vial still gives you 50 doses at 100mcg each), but you're now managing larger liquid volumes and must ensure your syringes can accommodate 0.3–0.5mL draws if your protocol escalates. Low-dose protocols benefit from smaller vial sizes (2.5mg instead of 5mg) to avoid exceeding the 28-day post-reconstitution stability window.

What If I Miss a Scheduled Dose and My Protocol Timing Is Off?

Administer the missed dose as soon as you realize the error if fewer than 24 hours have passed, then resume your regular schedule. If more than 24 hours have passed, skip the missed dose and continue with your next scheduled administration. Do not double-dose to compensate. SS-LUP-332's mechanism involves upregulation of genes involved in mitochondrial biogenesis and fatty acid oxidation, processes that take 48–72 hours to manifest at the cellular level, so single missed doses are unlikely to disrupt study outcomes provided your overall dosing frequency remains consistent. Document the deviation in your protocol notes.

What If My Reconstituted Vial Looks Cloudy or Has Visible Particles?

Discard it immediately. Properly reconstituted SS-LUP-332 should be clear and colorless. Cloudiness indicates either bacterial contamination or peptide aggregation, both of which render the solution unusable. Aggregation occurs when peptides denature and clump together, typically due to temperature excursions above 8°C or improper mixing technique (shaking instead of gentle swirling). Bacterial contamination presents as cloudiness that develops over days in a vial that was initially clear, often accompanied by a faint odor. Neither condition is reversible. Using contaminated or aggregated peptide introduces unknown variables into your research and poses safety risks.

The Unflinching Truth About SS-LUP-332 Dose Calculation

Here's the honest answer: most researchers waste 30–50% of their reconstituted SS-LUP-332 because they treat dose-per-vial calculation as a simple division problem instead of a stability-constrained optimization. The question isn't 'how many doses can I theoretically get from this vial'. It's 'how many doses can I use within 28 days given my protocol frequency, and what reconstitution volume keeps my measurement error under 5%?'

You can extract 40 doses from a 5mg vial at 125mcg each. But if you're dosing twice weekly, those 40 doses represent 20 weeks of administration. And your reconstituted peptide degrades after 28 days. The result: you'll use 8 doses and discard 32, turning an efficient vial into an expensive single-month supply. The fix isn't buying more vials. It's reconstituting less peptide per mixing event or increasing your dosing frequency to align usage with stability windows. Split-vial reconstitution, where you reconstitute half the lyophilized powder and leave the other half dry for later mixing, extends your effective vial lifespan without compromising peptide integrity. But that requires sterile technique most labs don't practice consistently.

The reconstitution volume you choose matters more than most protocol guides acknowledge. A 1mL reconstitution gives you high concentration and compact storage, but forces you into 0.05mL draws that insulin syringes can't measure reliably. A 4mL reconstitution gives you measurement precision, but you're now managing larger liquid volumes and burning through syringes faster. The optimal concentration for SS-LUP-332 sits at 2.5mg/mL (5mg vial + 2mL bacteriostatic water) because it keeps 250mcg doses at exactly 0.1mL. The injectable volume where standard insulin syringes maintain accuracy without wasting capacity.

Every vial of SS-LUP-332 you reconstitute starts a 28-day countdown. Plan your doses before you add the water.

Research-grade peptides demand precision at every step. From reconstitution math to syringe selection to cold-chain compliance. Our commitment to quality starts with small-batch synthesis and exact amino-acid sequencing, but it extends through every stage of handling and administration. If you're building protocols around selective PPAR agonism or other cutting-edge peptide mechanisms, explore our full peptide collection to see how lab-grade purity and consistent bioavailability support reproducible research outcomes.

The number of doses you get from one vial of SS-LUP-332 isn't fixed. It's a variable you control through reconstitution volume, protocol design, and measurement precision. Calculate your 28-day dose requirement before mixing, match your concentration to your syringe's accuracy range, and refrigerate immediately after every draw. Those three steps determine whether your vial yields 10 usable doses or 30.

Frequently Asked Questions

A 5mg vial of SS-LUP-332 yields 10–30 doses depending on your protocol dose per injection. At 250mcg per dose (the most common research protocol dose), one vial reconstituted with 2mL bacteriostatic water provides 20 doses. If your protocol calls for 500mcg per administration, the same vial gives you 10 doses. Lower doses (125mcg) theoretically yield 40 doses, but you’re limited by the 28-day post-reconstitution stability window and syringe measurement precision at very low injectable volumes.

For most SS-LUP-332 protocols, reconstituting a 5mg vial with 2mL bacteriostatic water creates the optimal 2.5mg/mL concentration. This allows 250mcg doses to be drawn as exactly 0.1mL (10 units on a standard insulin syringe), the volume at which measurement precision is highest and user error is minimized. Protocols requiring lower doses (under 200mcg) benefit from 3–4mL reconstitution to increase injectable volume, while high-dose protocols (above 500mcg) can use 1–2mL reconstitution to keep volumes manageable.

Once reconstituted with bacteriostatic water, SS-LUP-332 maintains stability for 28 days when refrigerated at 2–8°C in the original sterile vial. Temperature excursions above 8°C cause irreversible peptide degradation that neither visual inspection nor home testing can detect. Lyophilized (unmixed) SS-LUP-332 powder remains stable for 12–24 months when stored at −20°C. The 28-day post-reconstitution window is the critical constraint for dose planning — protocols requiring fewer than 8–10 administrations per month will waste peptide unless you reconstitute partial vials or adjust dosing frequency.

Yes, but only if you maintain sterile technique throughout the process. Split-vial reconstitution involves adding bacteriostatic water to only a portion of the lyophilized peptide, leaving the remaining powder dry until a future reconstitution event. This extends effective vial lifespan beyond the 28-day post-mixing stability window. The challenge is ensuring the unreconstituted portion remains sterile and dry — any moisture infiltration or contamination during the first draw compromises the remaining peptide. Most research labs lack the controlled environment needed for reliable split-vial protocols, making it safer to order smaller vial sizes (2.5mg instead of 5mg) if your protocol frequency is low.

Standard 0.3mL or 0.5mL insulin syringes with 1-unit graduations (0.01mL increments) are optimal for SS-LUP-332 administration. These syringes allow accurate measurement down to 0.05mL (5 units) and accommodate injectable volumes up to 0.3–0.5mL, covering the full range of typical protocol doses. Avoid 1mL syringes for doses under 0.3mL — the wider barrel reduces precision at low volumes. If your protocol requires doses above 500mcg (injectable volumes above 0.2mL at standard 2.5mg/mL concentration), a 0.5mL syringe provides the capacity you need while maintaining measurement accuracy.

Your total dose count per vial doesn’t change — a 5mg vial always contains 5mg of peptide regardless of how much water you add. What changes is the concentration (mg/mL), which determines how much liquid volume you must draw to get your target dose. Higher reconstitution volumes (3–4mL) create lower concentrations, requiring larger injectable volumes per dose — but the total number of doses remains constant. The practical constraint is syringe capacity: if your reconstitution volume is so high that each dose requires 0.4–0.5mL, you may need larger syringes or risk running out of barrel space, but you’re still extracting the same total peptide mass from the vial.

Injecting air into the vial while drawing creates positive pressure that forces liquid back through the needle on subsequent draws, increasing contamination risk over the vial’s 28-day lifespan. The immediate fix: draw your dose using a two-step technique — insert the needle, equalize pressure by drawing air out of the vial first, then inject that air back and draw your peptide solution. This keeps the vial at neutral pressure and prevents backflow. Air injection also creates bubbles in the solution that can interfere with accurate dose measurement. If you’ve already injected air multiple times, the vial isn’t ruined, but your contamination risk increases with each breach — consider using that vial within 14 days instead of the full 28-day window.

Degraded SS-LUP-332 often shows no visible signs — the solution can remain clear and colorless even after losing bioactivity due to temperature excursions or extended storage beyond the 28-day window. The only reliable indicators are: (1) cloudiness or visible particles, which signal aggregation or contamination and require immediate disposal, (2) development of an unusual odor, which suggests bacterial growth, or (3) protocol outcomes that deviate from expected dose-response patterns despite consistent administration. Peptide degradation is a molecular event you can’t see — the amino acid chain breaks down or misfolds, but the solution looks unchanged. This is why strict adherence to the 28-day refrigerated storage limit is non-negotiable.

Yes, SS-LUP-332 can be incorporated into multi-peptide research designs, but you must account for potential mechanistic interactions when interpreting results. SS-LUP-332 acts as a selective PPARδ agonist, influencing mitochondrial biogenesis and fatty acid oxidation pathways — mechanisms that overlap with some other research peptides targeting metabolic function. Co-administration with peptides affecting insulin signaling, GLP-1 pathways, or other metabolic targets may produce additive or synergistic effects that confound individual peptide attribution. Stagger administration times by at least 4–6 hours when possible, and document all concurrent protocols in study records to support accurate data interpretation.

SS-LUP-332 demonstrates high selectivity for the PPARδ receptor subtype, distinguishing it from pan-PPAR agonists that activate all three PPAR isoforms (alpha, gamma, delta) or compounds selective for PPARα or PPARγ. This selectivity matters because PPARδ activation drives mitochondrial biogenesis and oxidative metabolism pathways without the adipogenic effects associated with PPARγ agonism or the hepatic lipid metabolism changes linked to PPARα. Preclinical models suggest SS-LUP-332’s receptor selectivity allows targeted metabolic modulation with reduced off-target effects compared to earlier-generation PPAR ligands, though direct head-to-head comparative data in controlled research settings remains limited as of 2026.